Statement of Principles concerning rotator cuff syndrome (Reasonable Hypothesis) (No. 109 of 2022)

The SOP's core legal and medical concepts are set out in s 7, s 8, s 9, s 10 and Schedule 1. The central medical concept is "rotator cuff syndrome", which the instrument defines as a clinically symptomatic inflammatory or degenerative disorder of the rotator cuff or the long head of biceps and their associated bursae (s 7(2)(a)). The definition expressly lists included disorders,calcifying tendonitis, rotator cuff tear or rupture, impingement syndromes, tendinopathy/tendonitis, subacromial impingement, supraspinatus syndrome, and tendonitis of the long head of the biceps,and expressly excludes adhesive capsulitis of the shoulder (s 7(2)(b)-(c)). Notes clarify anatomy and the typical clinical presentation (persistent pain and tenderness that worsens with abduction into an overhead position) (s 7 Note 1-2).

A second major concept is the evidentiary test: the SOP states that "at least one" of a specified list of factors must exist before it can be said that a reasonable hypothesis has been raised connecting rotator cuff syndrome (or death from it) with relevant service (s 9). The factors are cumulative in form only insofar as at least one is required; they range across traumatic events (injury within 3 months before clinical onset, s 9(1)), surgical antecedents (s 9(2)), defined work‑ and sport‑related mechanical exposures with explicit quantitative thresholds (s 9(3)-(6), (24)-(26)), pharmacological exposures (fluoroquinolones, s 9(19); aromatase inhibitors, s 9(20); glucocorticoid use per Table 1 and equivalence Table 2 in Schedule 1), metabolic and systemic risk factors (diabetes, dyslipidaemia, gout, dialysis‑related amyloidosis, autoimmune diseases listed in Schedule 1), anatomical or structural contributors (anatomical narrowing of the subacromial space, joint instability, acquired scapular dyskinesis), and social/behavioural exposures (smoking at least 20 pack‑years) (s 9 and Schedule 1).

The SOP distinguishes between "clinical onset" and "clinical worsening", listing essentially the same set of factors twice,once in relation to clinical onset (s 9(1)-(20)) and again in relation to clinical worsening (s 9(21)-(40)),and adds "inability to obtain appropriate clinical management" as a factor for material contribution or aggravation (s 9(41)). Section 10 governs the relationship to service: any qualifying factor must be related to the person's relevant service (s 10(1)), and the subset of factors dealing with clinical worsening (s 9(21)-(41)) apply only where the person's rotator cuff syndrome was suffered or contracted before or during (but did not arise out of) their relevant service, because those factors are limited to material contribution to, or aggravation of, a pre‑existing condition (s 10(2)).

Schedule 1 supplies precise definitions that determine operational meaning. Examples: "injury to the affected shoulder" requires symptom onset within 24 hours of the precipitating event, and symptoms must persist for at least seven continuous days unless specific types of medical intervention occur (Schedule 1 definition). "Forceful activities" are quantified (equivalent to lifting/carrying more than 3 kg, or lifting/carrying >1 kg more than 10 times per hour) and the Schedule explicitly includes use of crutches and hand propulsion of wheelchairs (Schedule 1). The glucocorticoid tables provide both dose, route, duration and temporal proximity criteria for prednisolone and an equivalence table for other glucocorticoids (Schedule 1 Table 1 and Table 2). The SOP also defines "relevant service" to include the various service categories under the VEA and MRCA (Schedule 1).

Finally, s 11 links this SOP with other SOPs: if a factor in s 9 refers to an injury or disease covered by another SOP, the factors in that other SOP apply "in accordance with the terms of that Statement of Principles as in force from time to time" (s 11). In sum, the instrument is a textually detailed rulebook that converts a broad legal test,the "reasonable hypothesis" link to service,into a set of discrete, measurable medical and factual determinants.

This SOP affects claimants and decision‑makers operating within the VEA and MRCA entitlement frameworks. The instrument is explicitly applicable to "a claim to which section 120A of the VEA or section 338 of the MRCA applies" (s 5). That means it is engaged where a claimant seeks acceptance of rotator cuff syndrome (or death from it) in circumstances governed by those statutory claims pathways. The Schedule 1 definition of "relevant service" makes clear who counts as a covered person: those who rendered operational, peacekeeping, hazardous or British nuclear test defence service under the VEA, and those who rendered warlike or non‑warlike service under the MRCA (Schedule 1 definition of "relevant service"). Practically, that covers veterans and current/former members whose service falls within those statutory categories.

Those who must respond to the SOP include treating clinicians, medical assessors, claims officers and legal representatives preparing evidence for claims. The SOP stipulates precise evidence types and quantitative thresholds that claims need to meet to raise the reasonable hypothesis. For example, claimants whose work involved repetitive overhead shoulder activity will need to document hours and timing to hit the 80 hours in 120 consecutive days threshold (s 9(3)), or the 2,000 hours in 10 years threshold (s 9(4)); claimants with alleged pharmacological contributions must produce drug records showing fluoroquinolone use within 60 days (s 9(19)) or aromatase inhibitor use for at least 4 weeks within the 2 years before onset (s 9(20)). Claimants with prior shoulder injuries must show the injury produced the symptom cluster within 24 hours and persisting for at least seven days or else that medical intervention intervened as specified (Schedule 1 definition of "injury to the affected shoulder").

Employers, insurers and rehabilitation providers will be affected indirectly because the SOP sets evidentiary parameters that influence whether claims are accepted and whether compensation/rehabilitation entitlements are triggered. Where a factor overlaps with an injury/disease governed by another SOP, that other SOP's factors apply (s 11); thus claimants with co‑existing conditions may be required to meet criteria from more than one instrument.

The Repatriation Medical Authority and decision‑makers within the Department of Veterans' Affairs are directly affected by having to apply this SOP as the Authority's view on the medical‑scientific link between rotator cuff syndrome and service (s 3 and s 8). The SOP is the Authority's instrument for advising how a reasonable hypothesis is to be raised; insofar as administrative decision‑making under the VEA and MRCA relies on the RMA's SOPs, this instrument shapes the scope and lost‑or‑accepted claims.

The SOP also affects medical assessors who must interpret and apply Schedule 1 definitions such as "anatomical narrowing of the subacromial space" or "acquired scapular dyskinesis", because those definitions determine whether an imaging finding or clinical sign meets the statutory test (Schedule 1). Lastly, the SOP affects the families of deceased claimants where death is alleged to have been contributed to by rotator cuff syndrome; the instrument explicitly includes death from a terminal event that was contributed to by the person's rotator cuff syndrome (s 7(5); Schedule 1 definition of "terminal event").

This document is a Statement of Principles; it does not itself create criminal offences or civil causes of action, but it creates duties and evidentiary rights within the statutory claims process. The primary legal duty it imposes is on decision‑makers assessing claims under the VEA and MRCA to apply the factors set out and to treat the existence of at least one of those factors as sufficient to raise a reasonable hypothesis connecting rotator cuff syndrome (or death from it) with relevant service (s 9). The Authority made the SOP under s 196B(2) of the VEA (s 3), and the instrument's terms direct how the "reasonable hypothesis" threshold is to be operationalised.

Claimants have the right to have their claim considered against these factors; if they can adduce evidence meeting one or more of the listed factors, that will, as a matter of the SOP, meet the Authority's threshold for a reasonable hypothesis (s 9). For example, a claimant who demonstrates an injury to the affected shoulder within 3 months before clinical onset, where the injury satisfies the Schedule 1 definition, will satisfy one of the specified factors (s 9(1) and Schedule 1). Similarly, evidence of a qualifying work exposure (such as 2,000 hours of overhead shoulder activity in the preceding 10 years) or documented glucocorticoid use meeting the Table 1 criteria will satisfy a factor (s 9(4); Schedule 1 Table 1).

Decision‑makers effectively have a duty to treat s 11 as incorporating other SOPs where an identified factor refers to an injury/disease covered by another SOP; in that situation the other SOP's factors "apply in accordance with the terms of that Statement of Principles as in force from time to time" (s 11). There is therefore a procedural duty to cross‑reference and apply the terms of other SOPs where relevant.

The SOP also creates a delineation of causation modes. Section 10(1) requires that any factor in s 9 be related to the person's relevant service. Section 10(2) limits the subset of factors dealing with clinical worsening (s 9(21)-(41)) to situations where the rotator cuff syndrome pre‑existed service or was suffered/contracted before or during service but did not arise out of service; in those cases the factors apply only to material contribution to, or aggravation of, the pre‑existing condition. Thus claimants and decision‑makers must address both the timing of the condition relative to service and whether the relationship is one of causation, material contribution, or aggravation according to the wording of s 10.

The SOP grants no express enforcement powers or penalties; it is an evidentiary instrument to be used in administrative decision‑making (s 3, s 5). Rights to administrative review, merits review or judicial review that pertain to VEA/MRCA decisions are not created or altered by the SOP text itself; those processes are governed by other statutes and administrative law. The SOP does, however, alter the evidentiary baseline for those review exercises because it sets the RMA's authoritative view on the facts that raise a reasonable hypothesis.

Clinicians have a de facto duty to supply the specific clinical detail and timing the SOP demands if they want their opinions to be effective in the statutory claims context: for instance, to document whether an injection into the tendon region occurred within two weeks before onset (Schedule 1 Table 1), or to record the yearly accumulation of overhead activity hours to demonstrate the 2,000‑hour threshold (s 9(4)). Legal and medical practitioners preparing claims therefore have the right and obligation to tailor evidence to the SOP's quantifiable thresholds and definitional structures.

The instrument contains no penalty provisions, sanctioning powers, or criminal offences. It is an administrative statement made under subsection 196B(2) of the VEA (s 3) and applies to claims under specific statutory provisions (s 5). The SOP functions as an evidentiary and medical‑scientific standard for decision‑makers; it does not itself create enforcement mechanisms or prescribe penalties for non‑compliance. There is no indication in the text that contravening the SOP attracts fines, imprisonment, or other penal consequences.

Enforcement in practice occurs through the claims administration process set out elsewhere in the VEA and the MRCA. The SOP supplies the criteria that decision‑makers must apply when determining whether a reasonable hypothesis has been raised; acceptance or rejection of claims, adjustment of entitlements, or the provision of rehabilitation or other benefits will follow the statutory processes of the relevant Acts. Any penalties or consequences of a claim outcome (for example, benefit denial) derive from the VEA/MRCA decision‑making framework rather than from the SOP itself.

Because the SOP is a technical, medical‑evidentiary instrument, compliance or non‑compliance is operationally enforced by administrative adjudicators and medical assessors: if evidence does not meet any of the factors in s 9, a decision‑maker will not be able to treat the claim as meeting the reasonable hypothesis standard. The instrument therefore affects outcomes but not by imposing criminal or civil sanctions. The text provides no powers for inspection, coercive evidence gathering, or administrative fines; it simply prescribes the factual criteria that must be met to raise the reasonable hypothesis link to service.

The SOP also establishes inter‑instrument relations: s 11 requires that where a s 9 factor refers to an injury or disease covered by another SOP, the factors in that SOP "apply in accordance with the terms" of that SOP. This imposes a procedural enforcement mechanism in practice because decision‑makers must apply the relevant SOPs collectively where cross‑references exist. Again, any enforcement rests within the VEA/MRCA administrative apparatus and not within the SOP as an independent penal instrument.

Finally, the Schedule 1 definitions and thresholds (for example, numerical hours, drug dose and proximity limits) provide objective criteria that simplify assessment and reduce discretionary divergence. Those objective criteria operate as administrative constraints on how medical causation is to be treated in the claims process, thereby influencing enforcement of entitlement determinations through standardised application rather than through punitive measures.

The SOP is expressly made under VEA statutory authority (s 3) and applies to claims under specified provisions of the VEA and MRCA (s 5). It therefore interacts with the decision‑making and entitlement provisions of both Acts by supplying the RMA's medical‑scientific view of when a reasonable hypothesis is raised. Where factual factors in s 9 overlap with conditions regulated by other Statements of Principles, s 11 requires that the factors in those other SOPs apply according to their own terms: "the factors in that Statement of Principles apply in accordance with the terms of that Statement of Principles as in force from time to time" (s 11). That creates a mechanism for cross‑instrument application: decision‑makers must apply the relevant SOPs in combination when a factor references another SOP.

Section 7(3)-(4) introduces ICD‑10‑AM codes (M75.1, M75.2, M75.3, M74.4, M74.5) but clarifies that in applying this instrument "the meaning of rotator cuff syndrome is that given in subsection (2)." Thus the SOP uses ICD‑10‑AM codes for indexing medical record coding purposes while expressly prioritising the instrument's textual definition. The ICD‑10‑AM reference is to the Tenth Edition (effective 1 July 2017) (s 7(4)), tying medical classification interaction to a specified edition. Decision‑makers and clinicians must therefore reconcile clinical coding with the statutory definition provided.

Where factors refer to other diseases or exposures that are themselves regulated by other legislation or clinical guidelines (for example, dialysis‑related amyloidosis arising from dialysis practice or use of certain drugs governed by pharmaceutical regulation), the SOP treats those as medical facts to be proven. The Schedule 1 definition of "dialysis‑related amyloidosis" anchors the medical concept within the claims context; it does not alter clinical practice regulation, but it instructs how the administrative causation test treats that disease as a qualifying factor.

The instrument interacts with statutory causation concepts by distinguishing between onset and worsening and by requiring that factors be "related to the relevant service" (s 10(1)). For pre‑existing conditions, s 10(2) restricts certain factors to material contribution or aggravation where the condition was suffered or contracted before or during service but did not arise out of service. That interacts with the existing statutory frameworks for causation and aggravation within the VEA and MRCA, because it directs decision‑makers to apply these factors where the legal question is whether service materially worsened a pre‑existing disease.

Although the SOP is silent on procedural review rights, those procedural rights (merits review, judicial review, review by the Veterans' Review Board, etc.) are governed by the VEA, MRCA and general administrative law. The SOP's role is evidentiary: it determines how causation questions are to be framed under those broader procedural regimes. The SOP therefore interacts indirectly with those laws by changing the evidence landscape and thereby affecting available grounds and outcomes for review processes.

Finally, s 11's cross‑reference mechanism creates an ongoing interaction between SOPs: as other SOPs are amended or replaced, those changes will affect how s 9 factors that refer to other injuries/diseases operate. Decision‑makers therefore must monitor the current in‑force versions of other SOPs when applying s 11.

This instrument itself records a short amendment history. It was made under subsection 196B(2) of the VEA (s 3), dated 21 October 2022 (signature and sealer details appear on the instrument), and it commences operation on 21 November 2022 (s 2). Section 4 expressly repeals the earlier Statement of Principles concerning rotator cuff syndrome No. 100 of 2014 (Federal Register of Legislation No. F2014L01376), which had been made under subsections 196B(2) and (8) of the VEA. The instrument therefore functions as a replacement SOP, extinguishing the prior instrument's terms and substituting the revised factors and definitions contained here.

Beyond the direct repeal of SOP No. 100 of 2014, the instrument sets out in s 11 a mechanism that ensures its interaction with any future amendments to other SOPs: if a factor in s 9 refers to an injury or disease covered by another SOP, the factors in that other SOP apply "as in force from time to time" (s 11). That language means that this SOP, once in force, will continue to be responsive to later amendments of other SOPs without itself needing amendment to maintain coherence: decision‑makers must apply the then‑current versions of cross‑referenced SOPs.

The instrument contains its own detailed definitional schedule (Schedule 1) including numerically quantified thresholds and a glucocorticoid equivalence table. Any future amendment to the SOP would likely target those granular thresholds or definitions. The instrument does not, however, provide transitional provisions beyond the repeal of the prior SOP; it simply repeals the earlier instrument and enters into force on the stated date (s 2-4). Therefore, after 21 November 2022 the listed factors and definitions in this instrument are the operative ones for relevant claims falling under the specified statutory provisions (s 5).

The instrument's internal notes and examples (for instance examples of activities that may cause shoulder injury) are ancillary to the operative text but may provide interpretive guidance. If the RMA or the responsible Minister issues future instruments, those would be recorded as amendments or replacement SOPs in the Federal Register of Legislation; the text here commits decision‑makers to apply the version currently in force for the purposes of s 11 cross‑references.

Finally, the instrument's structure,definitional schedule, factor list for onset and worsening, linkage to other SOPs, and numerical thresholds,signals the RMA's approach to codifying evidentiary standards. Any future amendments are likely to focus on these operational elements (for example, threshold hours, drug proximity windows, or the list of specified autoimmune diseases), but those are speculative observations; the text itself records only the replacement of the 2014 SOP and the commencement date.

The instrument contains no references to litigation, judicial determination, or case law. It does not cite any court decisions or administrative review outcomes. The source document is an administrative medical standard issued by the Repatriation Medical Authority (s 3) and its text is confined to definitional and evidentiary matters; it records the RMA's view that "sound medical‑scientific evidence" supports the relationships stated (s 8), but it does not record litigation history.

Because the SOP is part of the statutory claims environment under the VEA and MRCA, decisions applying this SOP may be subject to administrative review and ultimately judicial review under the general Australian administrative law framework. The text itself does not refer to review pathways or past litigation testing the SOP's validity; nor does it identify any judicial challenges to the earlier No. 100 of 2014 SOP or to elements of the RMA's approach. The absence of litigation references in the instrument means there is no litigation history embedded in the text for practitioners to rely upon.

Practitioners should therefore treat the SOP as an authoritative administrative standard that could, in practice, be the subject of future merits or judicial review in the ordinary course if contested decisions arise under the VEA or MRCA. The instrument does not limit or specify review rights; those rights and any litigation history would be found in case law and decision records external to this instrument. Since the instrument does not itself record such materials, no litigation history is available inside the SOP.

In the absence of case citations or judicial interpretation in the instrument, users of the SOP should prepare for potential contestation over factual application (for example, the interpretation of the Schedule 1 definitions, the sufficiency of exposure documentation, or the assessment of "related to relevant service" under s 10) and rely on the textual detail of the SOP when assembling claims and evidence.

Several practical and legal pitfalls arise from the SOP's text that claimants, clinicians and decision‑makers should be alert to.

1. Textual primacy over ICD codes. Although ICD‑10‑AM codes are cited (s 7(3)-(4)), s 7(3) explicitly says the meaning of rotator cuff syndrome for the SOP is that given in s 7(2). Coding therefore assists record classification but does not replace the instrument's textual definition. A claim supported only by an ICD code without clinical detail matching s 7(2) risks failing to meet the SOP.

2. Dual lists for onset and worsening. The instrument duplicates most factors for both "clinical onset" (s 9(1)-(20)) and "clinical worsening" (s 9(21)-(40)). However, s 10(2) limits the latter list to cases where the condition pre‑existed service or was suffered/contracted before or during service but did not arise out of it. Practitioners must therefore establish the temporal sequence of disease relative to service to know which part of s 9 applies.

3. Numerical thresholds require precise evidence. Many factors depend on quantified exposures: 80 hours within 120 consecutive days (s 9(3)), 2,000 hours in 10 years (s 9(4) and s 9(26)), 200 hours of lifting/carrying ≥20 kg within 10 years (s 9(5)), 2,000 hours using vibrating heavy tools (s 9(6)). Supportive evidence must be detailed and time‑stamped. Vague statements about repetitive work generally will not meet these thresholds.

4. Short cessation window in s 9(3). For the 80‑hour/120‑day factor, the SOP requires the repetitive/sustained/forceful activities "have not ceased more than 30 days before the clinical onset" (s 9(3)). This 30‑day cessation requirement is a narrow window that can be fatal to claims where the exposure stopped earlier.

5. Definition of "injury to the affected shoulder" is strict. Schedule 1 requires symptom onset within 24 hours of the precipitating event and symptoms that persist for at least seven continuous days, unless specific medical interventions (immobilisation, injection, surgery) occurred. If onset is delayed beyond 24 hours or reported symptoms were masked by analgesia and not documented upon return to consciousness, claimants may fail to meet the definition.

6. Glucocorticoid dosing complexities. The Schedule 1 Table 1 sets out dose, route, duration and proximity windows for prednisolone (for example, IV/IM/oral ≥0.5 grams over 6 months within the 3 years before onset, or injection in tendon region ≥1 injection within 2 weeks). Table 2 provides conversion ratios for other glucocorticoids. Errors in converting doses or failures to document route/duration/timing precisely will jeopardise reliance on this factor.

7. Pharmacological timing windows. Fluoroquinolone exposure must be within 60 days before onset (s 9(19)), aromatase inhibitors must have been taken for at least 4 weeks within the two years before onset (s 9(20)). Shorter or earlier exposure may not qualify.

8. Smoking pack‑year calculation is prescriptive. The SOP defines "one pack‑year" and gives a calculation method in Schedule 1. A failure to calculate pack‑years according to the instrument's formula or to document smoking history may undermine reliance on the smoking factor (s 9(15)).

9. "Inability to obtain appropriate clinical management" is a factor for worsening (s 9(41)). The SOP does not define what constitutes "appropriate clinical management" or how inability is evidenced; claimants relying on this factor must therefore assemble detailed clinical correspondence, appointment logs, or records of treatment delays to substantiate this subjective element.

10. Exclusion of adhesive capsulitis. The SOP expressly excludes adhesive capsulitis of the shoulder (s 7(2)(c)). Claims that rest on adhesive capsulitis labels must be re‑characterised to fit the SOP's included conditions or fail.

11. Cross‑reference to other SOPs. If a factor refers to another disease covered by another SOP, that SOP's terms apply (s 11). Practically, this can require assembling and satisfying two SOPs' factors, which may have different thresholds or definitions.

12. Death inclusion is limited to contributions to terminal events. The SOP includes death only where rotator cuff syndrome "contributed to" a terminal event or condition listed in Schedule 1 (pneumonia, respiratory failure, cardiac arrest, circulatory failure, cessation of brain function) (s 7(5); Schedule 1 definition of "terminal event"). Causation links here will be scrutinised by clinical and medico‑legal assessors.

13. Evidence of anatomical narrowing, instability, or bursitis requires objective confirmation. Factors such as "anatomical narrowing of the subacromial space", "joint instability/dislocation/subluxation", or "infection of the subacromial/subdeltoid bursa" depend on imaging or clinical signs; subjective reports alone are unlikely to suffice (s 9(9), s 9(10), s 9(11)).

14. Time lag from RMA view to administrative practice. The SOP states the RMA's view (s 8). Administrative actors may require further evidentiary steps to operationalise that view; claimants should not assume automatic acceptance by administrative decision‑makers without meeting the specific factors.

These "gotchas" arise directly from textual thresholds and definitional strictures in the SOP; practitioners should work to anticipate and remedy each by assembling targeted, time‑stamped objective evidence.

Compliance, from the perspective of claim preparation and administrative proof, means assembling evidence that satisfies at least one of the factors in s 9 and demonstrating the required relationship to relevant service under s 10. The following practical steps translate the SOP's textual requirements into evidence‑gathering actions.

1. Identify the applicable statutory pathway. Confirm the claim is one to which s 120A of the VEA or s 338 of the MRCA applies (s 5). Confirm the claimant's "relevant service" category per the Schedule 1 definition (operational, peacekeeping, hazardous, British nuclear test defence service under the VEA; warlike or non‑warlike service under the MRCA).

2. Establish diagnosis per the SOP definition. Ensure clinical records document a diagnosis matching s 7(2): a clinically symptomatic inflammatory or degenerative rotator cuff disorder or long head of biceps disorder, excluding adhesive capsulitis. While ICD‑10‑AM codes may be included (s 7(3)-(4)), the clinical narrative must align with the textual definition.

3. Select the applicable factor(s) in s 9 and assemble tailored evidence:

   • Trauma/sudden injury (s 9(1) and s 9(21)): Document the precipitating incident, timing within 24 hours of symptom onset, and continuity of symptoms for at least 7 days, or the medical interventions listed in Schedule 1. Hospital notes, emergency department records, imaging performed immediately after the event, and contemporaneous GP notes are critical.

   • Surgical antecedent (s 9(2) and s 9(22)): Provide operative notes, anaesthetic records and post‑operative follow‑up indicating the timing of surgery relative to clinical onset/worsening.

   • Repetitive/forceful/overhead activities (s 9(3)-(6), s 9(23)-(26)): Quantify hours and dates. For the 80 hours/120 days factor (s 9(3)), create a timeline showing the concentration of repetitive or forceful activity, and confirm the activity did not cease more than 30 days before onset. For the 2,000 hours/10 years factor (s 9(4)), assemble employment records, rosters, duty statements, time sheets, sporting participation logs, or sworn affidavits corroborating cumulative hours. For lifting/carrying thresholds (s 9(5)), show documented tasks involving loads ≥20 kg and the number of hours. For tool‑use thresholds (s 9(6)), provide maintenance logs, time‑in‑service reports or site records showing use of vibrating heavy industrial tools.

   • Weight‑bearing upper limbs (s 9(8)): Document transfers, use of crutches or wheelchair propulsion with dates and durations where possible.

   • Structural/anatomical factors (s 9(9), s 9(10), s 9(11), s 9(29)-(31)): Include imaging (X‑ray, MRI, ultrasound), orthopaedic specialist reports, and surgery records confirming narrowing, instability, dislocation history, bursitis, or infection.

   • Systemic or metabolic risks (s 9(7), s 9(12), s 9(13), s 9(16)-(17), s 9(35)): Produce pathology reports demonstrating dialysis‑related amyloidosis, blood lipid panels and records of lipid‑normalising therapy for dyslipidaemia, diabetes diagnostic and management records, gout diagnosis notes, and documentation of specified autoimmune diseases in the Schedule 1 list.

   • Smoking history (s 9(15)): Calculate pack‑years as per Schedule 1 method. Provide GP notes, smoking cessation records, or a sworn statement corroborated by contemporaneous medical entries.

   • Pharmacological exposures (s 9(18)-(20), s 9(38)-(40)): For glucocorticoids, document drug, dose, route, duration and dates so the claim can be matched to Schedule 1 Table 1 thresholds; if using drugs other than prednisolone, apply Table 2 conversion ratios. For fluoroquinolones, produce dispensing records proving use within 60 days prior to onset. For aromatase inhibitors, show at least 4 weeks of therapy within the prior two years to onset.

   • Inability to obtain management (s 9(41)): Compile appointment records, referral correspondence, waiting list dates, clinical letters showing treatment refusal or unavailability, and any communications demonstrating inability to obtain appropriate care.

4. Demonstrate relation to relevant service. For any s 9 factor relied upon, produce evidence linking that factor to service activities or events. For example, if the factor is repetitive overhead work, show duty statements, deployment rosters, trade descriptions, or unit logs indicating those tasks formed part of service. For an injury claimed to have occurred during service, include incident reports, service medical records noting the acute injury, and contemporaneous entries.

5. Address onset versus worsening. Establish whether the claim concerns clinical onset or clinical worsening. If asserting material contribution or aggravation of a pre‑existing rotator cuff syndrome that predates service, note that s 10(2) confines subsections 9(21)-(41) to material contribution/aggravation. Provide pre‑service medical records and evidence of baseline function to demonstrate how service materially changed the condition.

6. Reconcile cross‑referenced SOPs. If any factor touches on an injury or disease covered by another SOP (s 11), identify that SOP and assemble evidence to meet its factors in addition to this SOP's factors. Monitor the in‑force status of other SOPs, because s 11 requires application of the other SOP "as in force from time to time".

7. Use objective contemporary records where possible. The SOP's quantitative thresholds and proximity windows make contemporaneous records of high evidentiary value: employment logs, pharmacy dispensing records, imaging dated and reported by a specialist, operation records, and service reports. Affidavits and retrospective estimates are secondary and should be corroborated by other documentation.

8. Document chronological sequencing. Build a clear timeline showing dates of exposure, injury, pharmacological use, onset of symptoms, and relation to service. For the 30‑day cessation requirement in s 9(3) and the proximity windows in Schedule 1 Table 1, precise sequencing is decisive.

9. Prepare medical opinion letters that map the medical narrative to the SOP. Clinicians and medical assessors should be asked to state explicitly whether, on the balance of probabilities, the claimant meets the specific factor(s) in s 9, and to reference the relevant Schedule 1 definitions and glucocorticoid tables when addressing pharmacological or systemic factors. Opinions that merely state a general causal relationship without mapping to the SOP thresholds risk being unhelpful.

10. For death claims, link rotator cuff syndrome to the terminal event. If asserting that rotator cuff syndrome contributed to death, obtain the death certificate, post‑mortem report where available, and clinical summaries showing how shoulder disease contributed to the terminal event (as the Schedule 1 "terminal event" list limits the causal endpoints).

11. Record conversions for glucocorticoids accurately. When prednisolone equivalents are used, apply Table 2 conversion ratios precisely and document the calculation. For prednisolone itself, ensure the total cumulative dose, route and timing match Table 1 criteria. Also document any tendon injections and their timing.

12. Anticipate cross‑examination on subjective factors. For factors such as "regularly using upper limbs for weight‑bearing" or "inability to obtain appropriate clinical management", compile corroborative documentation (therapy notes, equipment loan records, rehabilitation notes) to substantiate claims beyond the claimant's statement.

13. Keep track of in‑force SOPs. Because s 11 refers to other SOPs "as in force from time to time", ensure submitted claims reference the current versions of any cross‑referenced SOPs.

Following these steps aligns claim preparation with the SOP's textual requirements and improves the chance that an administrative decision‑maker will find that a reasonable hypothesis has been raised in accordance with the RMA's specified factors.